GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » E10

ChemoCentryx (ChemoCentryx) E10 : $-1.13 (As of Jun. 2022)


View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ChemoCentryx's adjusted earnings per share data for the three months ended in Jun. 2022 was $-0.440. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.13 for the trailing ten years ended in Jun. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-26), ChemoCentryx's current stock price is $51.99. ChemoCentryx's E10 for the quarter that ended in Jun. 2022 was $-1.13. ChemoCentryx's Shiller PE Ratio of today is .


ChemoCentryx E10 Historical Data

The historical data trend for ChemoCentryx's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx E10 Chart

ChemoCentryx Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -0.78 -0.82 -1.04

ChemoCentryx Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.90 -0.90 -1.04 -1.09 -1.13

Competitive Comparison of ChemoCentryx's E10

For the Biotechnology subindustry, ChemoCentryx's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ChemoCentryx's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ChemoCentryx's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ChemoCentryx's Shiller PE Ratio falls into.



ChemoCentryx E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ChemoCentryx's adjusted earnings per share data for the three months ended in Jun. 2022 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2022 (Change)*Current CPI (Jun. 2022)
=-0.44/125.0168*125.0168
=-0.440

Current CPI (Jun. 2022) = 125.0168.

ChemoCentryx Quarterly Data

per share eps CPI Adj_EPS
201209 -0.280 97.633 -0.359
201212 -0.280 96.871 -0.361
201303 -0.280 98.209 -0.356
201306 -0.230 98.518 -0.292
201309 -0.220 98.790 -0.278
201312 -0.220 98.326 -0.280
201403 -0.270 99.695 -0.339
201406 -0.280 100.560 -0.348
201409 -0.250 100.428 -0.311
201412 -0.280 99.070 -0.353
201503 -0.280 99.621 -0.351
201506 -0.280 100.684 -0.348
201509 -0.260 100.392 -0.324
201512 -0.260 99.792 -0.326
201603 -0.340 100.470 -0.423
201606 -0.220 101.688 -0.270
201609 -0.150 101.861 -0.184
201612 -0.160 101.863 -0.196
201703 -0.120 102.862 -0.146
201706 -0.190 103.349 -0.230
201709 -0.130 104.136 -0.156
201712 0.800 104.011 0.962
201803 -0.190 105.290 -0.226
201806 -0.140 106.317 -0.165
201809 -0.220 106.507 -0.258
201812 -0.210 105.998 -0.248
201903 -0.230 107.251 -0.268
201906 -0.260 108.070 -0.301
201909 -0.220 108.329 -0.254
201912 -0.260 108.420 -0.300
202003 -0.350 108.902 -0.402
202006 0.290 108.767 0.333
202009 -0.350 109.815 -0.398
202012 -0.430 109.897 -0.489
202103 -0.430 111.754 -0.481
202106 -0.560 114.631 -0.611
202109 -0.320 115.734 -0.346
202112 -0.580 117.630 -0.616
202203 -0.550 121.301 -0.567
202206 -0.440 125.017 -0.440

Add all the adjusted EPS together and divide 10 will get our e10.


ChemoCentryx  (NAS:CCXI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ChemoCentryx E10 Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


ChemoCentryx (ChemoCentryx) Business Description

Traded in Other Exchanges
N/A
Address
835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Executives
Susan M Kanaya officer: SVP Finance, CFO & Secretary 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall director, 10 percent owner, officer: President, CEO and Director 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau officer: SVP, Finance & Acctg Officer C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon director C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt officer: EVP, Chief Operating Officer C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker director 15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards director C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel officer: CBO and Treasurer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan officer: Principal Acctg Officer 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh officer: SVP, Research C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027

ChemoCentryx (ChemoCentryx) Headlines

From GuruFocus

ChemoCentryx Announces Changes to its Board of Directors

By GuruFocusNews GuruFocusNews 07-10-2022